Novo Nordisk of Denmark, considered as world’s biggest producer of insulin has commented that Phase III study has shown that people who are treated with their liraglutide drug can experience 8% in weight loss.
The data and the findings of the Phase III study are extremely consistent in showing the positive improvements of the obese people who are taking the drugs produced by Novo Nordisk Company. This statement is backed up by Mads Krogsgaard Thomsen, chief science officer.
The product’s efficiency and the volume of its data are still debated by various experts and analysts. Novo has recently declined in revealing their in-house forecast but stated that their new product would cost around 20$ per day which will take fewer patients around 150,000 to be able to make it a 1 billion-a-year product.
The new drug is already out in various markets and aims to treat type 2 diabetes under its brand’s name of Victoza.
Novo is hoping that with the release of this product, the FDA will finally approve it after rejecting another product Tresiba that resulted in demanding new studies about the cardiovascular risks and dangers.
Last March, Novo has reported that those obese and diabetic patients who are provided with high doses of the liraglutide drug have experienced positive improvements to their weights and condition.
According to the report, the average weight loss of their obese patients is 8.0 percent compared to 2.6 % of those who are treated with placebo.
Novo Nordisk is hoping and expecting that the Phase III study will be completed in the third semester of the year and file their drug for a review to treat this product as treatment for obesity and diabetes.